 | Up a level |
Rajeev, Surya, Roberts, Carl 
ORCID: 0000-0003-4275-601X, Brown, Emily, Sprung, Victoria ORCID: 0000-0002-2666-4986, Harrold, Jo ORCID: 0000-0002-0899-4586, Halford, Jason ORCID: 0000-0003-1629-3189, Stancak, Andrej ORCID: 0000-0003-3323-3305, Boyland, Emma ORCID: 0000-0001-8384-4994, Kemp, Graham ORCID: 0000-0002-8324-9666, Perry, Julie et al (show 4 more authors)
(2023)
No evidence of compensatory changes in energy balance, despite reductions in body weight and liver fat, during dapagliflozin treatment in type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled, cross-over trial (ENERGIZE).
Diabetes, Obesity and Metabolism: a journal of pharmacology and therapeutics, 25 (12).
pp. 3621-3631.
Brown, Emily, Wilton, Moon M ORCID: 0000-0003-4052-7918, Sprung, Victoria S ORCID: 0000-0002-2666-4986, Harrold, Joanne A ORCID: 0000-0002-0899-4586, Halford, Jason CG ORCID: 0000-0003-1629-3189, Stancak, Andrej ORCID: 0000-0003-3323-3305, Burgess, Malcolm, Howarth, Elaine, Umpleby, A Margot, Kemp, Graham J ORCID: 0000-0002-8324-9666 et al (show 2 more authors)
(2021)
A randomised, controlled, double blind study to assess mechanistic effects of combination therapy of dapagliflozin with exenatide QW versus dapagliflozin alone in obese patients with type 2 diabetes mellitus (RESILIENT): study protocol.
BMJ open, 11 (7).
e045663-e045663.